These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35110451)

  • 21. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.
    Chen D; Frezza M; Schmitt S; Kanwar J; Dou QP
    Curr Cancer Drug Targets; 2011 Mar; 11(3):239-53. PubMed ID: 21247388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.
    Dou QP; Zonder JA
    Curr Cancer Drug Targets; 2014; 14(6):517-36. PubMed ID: 25092212
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Boron in drug design: Recent advances in the development of new therapeutic agents.
    Fernandes GFS; Denny WA; Dos Santos JL
    Eur J Med Chem; 2019 Oct; 179():791-804. PubMed ID: 31288128
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome.
    Groll M; Berkers CR; Ploegh HL; Ovaa H
    Structure; 2006 Mar; 14(3):451-6. PubMed ID: 16531229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors.
    Golden EB; Lam PY; Kardosh A; Gaffney KJ; Cadenas E; Louie SG; Petasis NA; Chen TC; Schönthal AH
    Blood; 2009 Jun; 113(23):5927-37. PubMed ID: 19190249
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Proteasome inhibitor].
    Yagi H
    Nihon Rinsho; 2014 Jun; 72(6):1125-9. PubMed ID: 25016815
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dipeptide boronic acid inhibitors of dipeptidyl peptidase IV: determinants of potency and in vivo efficacy and safety.
    Connolly BA; Sanford DG; Chiluwal AK; Healey SE; Peters DE; Dimare MT; Wu W; Liu Y; Maw H; Zhou Y; Li Y; Jin Z; Sudmeier JL; Lai JH; Bachovchin WW
    J Med Chem; 2008 Oct; 51(19):6005-13. PubMed ID: 18783201
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Boronic ester-linked macrocyclic lipopeptides as serine protease inhibitors targeting Escherichia coli type I signal peptidase.
    Szałaj N; Lu L; Benediktsdottir A; Zamaratski E; Cao S; Olanders G; Hedgecock C; Karlén A; Erdélyi M; Hughes D; Mowbray SL; Brandt P
    Eur J Med Chem; 2018 Sep; 157():1346-1360. PubMed ID: 30196059
    [TBL] [Abstract][Full Text] [Related]  

  • 29. From bortezomib to other inhibitors of the proteasome and beyond.
    Buac D; Shen M; Schmitt S; Kona FR; Deshmukh R; Zhang Z; Neslund-Dudas C; Mitra B; Dou QP
    Curr Pharm Des; 2013; 19(22):4025-38. PubMed ID: 23181572
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peptide boronic acids. Versatile synthetic ligands for affinity chromatography of serine proteinases.
    Zembower DE; Neudauer CL; Wick MJ; Ames MM
    Int J Pept Protein Res; 1996 May; 47(5):405-13. PubMed ID: 8791164
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design.
    Schrader J; Henneberg F; Mata RA; Tittmann K; Schneider TR; Stark H; Bourenkov G; Chari A
    Science; 2016 Aug; 353(6299):594-8. PubMed ID: 27493187
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.
    Pekol T; Daniels JS; Labutti J; Parsons I; Nix D; Baronas E; Hsieh F; Gan LS; Miwa G
    Drug Metab Dispos; 2005 Jun; 33(6):771-7. PubMed ID: 15764713
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib.
    Cvek B; Dvorak Z
    Curr Pharm Des; 2011; 17(15):1483-99. PubMed ID: 21504411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor extracellular acidity activated "off-on" release of bortezomib from a biocompatible dendrimer.
    Wang M; Wang Y; Hu K; Shao N; Cheng Y
    Biomater Sci; 2015 Mar; 3(3):480-9. PubMed ID: 26222291
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pro-soft Val-boroPro: a strategy for enhancing in vivo performance of boronic acid inhibitors of serine proteases.
    Poplawski SE; Lai JH; Sanford DG; Sudmeier JL; Wu W; Bachovchin WW
    J Med Chem; 2011 Apr; 54(7):2022-8. PubMed ID: 21388136
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proteasome inhibitors.
    Teicher BA; Tomaszewski JE
    Biochem Pharmacol; 2015 Jul; 96(1):1-9. PubMed ID: 25935605
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacophore modeling, docking studies, and synthesis of novel dipeptide proteasome inhibitors containing boron atoms.
    Lei M; Zhao X; Wang Z; Zhu Y
    J Chem Inf Model; 2009 Sep; 49(9):2092-100. PubMed ID: 19691298
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel proteasome inhibitors to overcome bortezomib resistance.
    Ruschak AM; Slassi M; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2011 Jul; 103(13):1007-17. PubMed ID: 21606441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proteasome inhibitors in cancer therapy.
    Testa U
    Curr Drug Targets; 2009 Oct; 10(10):968-81. PubMed ID: 19548862
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acid-labile boronate-bridged dextran-bortezomib conjugate with up-regulated hypoxic tumor suppression.
    Xu W; Ding J; Li L; Xiao C; Zhuang X; Chen X
    Chem Commun (Camb); 2015 Apr; 51(31):6812-5. PubMed ID: 25787235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.